Probiodrug - Spotlight on Abeta MAbs after Biogen’s data
The surprise announcement of the disease-modifying effect obtained by Biogen and Eisai with their MAb BAN2401 in a Phase II trial announced during...
53 Views
Probiodrug - Support for Abeta theory from Biogen/Eisai
We believe one of the main reasons for the devaluation of Probiodrug’s shares over the past year was the largely disappointing industry newsflow...
48 Views
Probiodrug - Emerging details of PQ912 late-stage development
The highlight of Probiodrug’s FY17 results presentation was the rather detailed introduction of the Phase IIb development programme for the lead...
77 Views
Focusing on further PQ912 development strategy
Operating costs in H117 were largely in line with our expectations, while a one-off payment was a welcome resolution of Probiodrug’s...
90 Views
First data paint a positive overall picture
Probiodrug presented the first data from its flagship Phase IIa clinical trial with its lead drug candidate PQ912, a glutaminyl cyclase (QC)...
130 Views
No more insights